Immunity to HAV and HBV remains low among US adults, including high-risk populations with chronic liver or kidney disease.

Influenza mortality increased among US children over 25 years despite declines in other vaccine-preventable deaths.

Ceftazidime-avibactam therapy yields a high clinical response rate in patients with MDR Gram-negative pneumonia in routine practice.

Nirsevimab immunization effectively decreases the risk for RSV-related LRTI hospitalizations in an infant's first year.

Real-world data demonstrate that nirsevimab and maternal vaccination protect infants against severe RSV outcomes.

From 2015 to 2023, US MenB rates remained low, marked by significant regional and demographic disparities.

Updated BNT162b2 KP.2 vaccination reduces COVID-19 hospitalizations and ED visits in immunocompetent adults regardless of risk status.

Oseltamivir reduces ICU admission risk and shortens hospital stays in pediatric patients hospitalized with influenza.

Integrating community pharmacies into the HIV prevention landscape offers accessible, disease-agnostic entry points for PrEP and care.

Dr Marissa Robinson discusses structural barriers to HIV PrEP access and strategies to enhance health equity in care delivery.

Dr Marissa Robinson discusses structural barriers to HIV PrEP access and strategies to enhance health equity in care delivery.

Shingles is caused by a reactivation of the varicella zoster virus, leading to a painful rash and postherpetic neuralgia if left untreated.

Dietary counseling improves lipid profiles in people with HIV, whereas exercise training significantly increases HDL-C levels.

Baseline obesity in adults initiating ART may worsen long-term comorbidity and mortality risks, particularly in younger patients.

Infectious Disease Advisor provides news updates and key opinion leader interviews from USCHA 2026, held in Anaheim, California.

Researchers evaluated changes in inpatient all-cause pneumonia rates among US adults before and after the introduction of the 13-valent pneumococcal conjugate vaccine.

Adults with SAB experience higher 30-day mortality rates when accompanied by recent SARS-CoV-2 infection.

The AAP has updated its RSV immunization guidelines for the 2026-2027 season, expanding the high-risk criteria for children entering their second season.

mRNA-1345 vaccination is associated with a reduced risk for RSV-associated ARI hospitalization in US veterans.

Short-term PM2.5 exposure combined with cardiovascular conditions raises COVID-19 pneumonia risk in hospitalized patients.

Adjunctive corticosteroid therapy is associated with reduced mortality in adult and pediatric patients with TBM.

Restricting age for RV administration limits immunization rates, with delayed DTaP initiation linked to higher non-initiation.

Coccidioidomycosis represents a frequent cause of community-acquired pneumonia among hospitalized patients in endemic regions.

Pediatric MRSA hospitalizations declined between 2016 and 2024, but ICU admission rates remained stable alongside shifts in drug selection.

Preinfection COVID-19 vaccination lowers the risk for persistent post-COVID-19 conditions in children and adolescents.

Prolonged bacteremia in pediatric AHOAI increases early complications but does not dictate long-term orthopedic outcomes.

Universal neonatal HBV vaccination and low baseline levels are linked to HBsAg seroclearance in HIV/HBV coinfection.

Treatment-naive adults with HIV-1 who suppress on DTG/3TC can successfully transition to LA CAB/RPV.

DTG/3TC achieves noninferior virologic suppression when compared with BIC/FTC/TAF in adults initiating first-line ART for HIV-1.

Anti-inflammatory and antihistamine therapies offer short-term fatigue relief in long COVID, but long-term benefit is unlikely.

TZP resistance in E coli or K pneumoniae bloodstream infections does not independently increase 30-day mortality risk.

Hospitalized children experienced a decrease in influenza vaccination rates following the COVID-19 pandemic.

Evaluation of US pediatric data confirms no association between early childhood MMR vaccination and autism diagnosis.

The 9vHPV vaccine protects young men against 6-month persistent anogenital infection with vaccine-covered types.

Revised ACC immunization guidance provides evidence-based recommendations for influenza, pneumococcal, COVID-19, RSV, and zoster vaccines.

Early remdesivir therapy reduces all-cause graft loss and CV event risks in KT recipients with acute symptomatic COVID-19.

Oral gepotidacin yields NAAT-based success rates comparable with ceftriaxone plus azithromycin in uncomplicated urogenital gonorrhea.

President Trump signed an executive order revising childhood vaccine recommendations to reduce and space out immunization schedules.

Evolving guidance and gaps in routine immunization present ongoing challenges for clinicians advocating for vaccine counseling.

Nirsevimab immunization in infants younger than 12 months is associated with a significantly reduced risk for IPD.

Delayed antibiotics increase in-hospital mortality only in patients presenting with septic shock, irrespective of immune status.

Surveillance data show AI/AN children younger than 5 years face higher rates of RSV-related hospitalization than their peers in the general US population.

PCV15 elicits superior immune responses against pneumococcal serotypes 22F and 33F compared with PCV13 with similar overall safety.

The FDA has approved Mucinex 12HR Cold & Fever Multi-Symptom, an OTC product for the relief of common cold symptoms.

A retrospective study shows rising sepsis-related mortality in older adults with influenza or pneumonia, peaking in 2021.

The 2024-2025 US influenza vaccine provided moderate protection against outpatient illness, reducing medically attended visits by one-third.

Postoperative risks for sepsis and pulmonary embolism are highest when joint arthroplasty occurs within 4 weeks of COVID-19 diagnosis.